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Sox6 belongs to the Sox gene family and plays a
pivotal role in fiber type differentiation, suppressing
transcription of slow-fiber-specific genes during fetal
development. Here, we show that Sox6 plays oppo-
site roles in MyHC-I regulation, acting as a positive
and negative regulator of MyHC-I expression dur-
ing embryonic and fetal myogenesis, respectively.
During embryonic myogenesis, Sox6 positively regu-
lates MyHC-I via transcriptional activation of Mef2C,
whereas during fetal myogenesis, Sox6 requires
and cooperates with the transcription factor Nfix in
repressing MyHC-I expression. Mechanistically,
Nfix is necessary for Sox6 binding to the MyHC-I
promoter and thus for Sox6 repressive function,
revealing a key role for Nfix in driving Sox6 activity.
This feature is evolutionarily conserved, since the
orthologs Nfixa and Sox6 contribute to repression
of the slow-twitch phenotype in zebrafish embryos.
These data demonstrate functional cooperation be-
tween Sox6 andNfix in regulatingMyHC-I expression
during prenatal muscle development.
INTRODUCTION
In vertebrates, the process of skeletal muscle development oc-
curs in subsequent steps that involve distinct populations of
myogenic progenitors, the myoblasts, which arise from the der-
momyotomal domain of somitic mesoderm (Christ and Ordahl,
1995). The process of myogenic differentiation is initiated in
mesodermal cells by a family of basic-helix-loop-helix (bHLH)
transcription factors, named muscle regulatory factors (MRFs),
that are able to activate transcription of muscle-specific markers
such as the myosin heavy chain (MyHC) isoforms (Pinney et al.,
1988; Cao et al., 2010). Embryonicmyoblasts sustain a first wave
of myogenesis between embryonic day 10 (E10) and E12 in the
mouse and give rise to primarymyofibers that establish the prim-2354 Cell Reports 17, 2354–2366, November 22, 2016 ª 2016 The A
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isoform (MyHC-I, encoded by theMyh7 gene) and of the embry-
onic MyHC isoform (MyHC-emb, encoded by Myh3) (Schiaffino
et al., 1986; Stockdale, 1992). A secondwave of muscle differen-
tiation takes place between E15 and E18, driven by fetal myo-
blasts that form secondary fibers, characterized by low levels
of MyHC-I and high levels of neonatal MyHC (MyHC-neo, en-
coded by Myh8) (Eusebi et al., 1986; Lyons et al., 1990; Daou
et al., 2013). Eventually, primary fibers conserve the slow-twitch
phenotype typical of embryonic muscle, while secondary fibers
lose the expression of several embryonic-specific markers
such as MyHC-I and acquire expression of fast-twitch markers
(Ferrari et al., 1997; Biressi et al., 2007). Embryonic and fetal
myoblasts, once isolated from the embryo, are committed to a
specific fiber type, suggesting the involvement of intrinsic factors
rather than nerve activity in the establishment of fiber phenotype
(Page et al., 1992). These observations suggest that the proper
transition of skeletal muscle from the embryonic to the fetal/
post-natal phenotype requires a switch in the transcriptional sta-
tus of differentiating myoblasts.
In our previous study, we have shown that the transcription
factor Nfix, a member of the nuclear factor I (Nfi) family, has a
key role in the establishment of fetal muscle phenotype and in
the downregulation of slowMyHCboth in fetal and adult muscles
(Messina et al., 2010; Rossi et al., 2016). We have shown that
Nfix is strongly expressed in fetal myoblasts and indirectly re-
presses MyHC-I expression via the transcription factor Nfatc4,
a positive regulator of MyHC-I in skeletal muscle (Calabria
et al., 2009; Messina et al., 2010). We have also reported that
the zebrafish (Danio rerio) Nfix ortholog Nfixa has an evolution-
arily conserved role in the transition from slow-twitch to fast-
twitch myogenesis (Pistocchi et al., 2013). In the past few years,
it has been shown that Sox6, a member of the Sry-related HMG
box (Sox) factor family, which is highly conserved in vertebrates,
plays a critical role in fetal fiber specification through direct
repression of MyHC-I by binding to the 50-upstream region in
two different binding sites. The first is located 200 bp from
the transcription start site (TSS) in the proximal promoter and
is sufficient for Sox6-dependent MyHC-I repression in fetal my-
otubes (Hagiwara et al., 2007; An et al., 2011), and the seconduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
is located 2,900 bp from the TSS in a distal muscle enhancer
that is required for full promoter activity (Giger et al., 2000;
Blow et al., 2010). As a consequence, Sox6-null mouse muscle
displays increased levels of MyHC-I and a general switch toward
a slower phenotype (Hagiwara et al., 2007; An et al., 2011; Quiat
et al., 2011). Of note, studies in zebrafish have shown that Sox6
is restricted to fast-twitch fibers during embryonic muscle devel-
opment and that ectopic Sox6 expression in adaxial cells (the
slow muscle progenitors in zebrafish) leads to the silencing of
slow-twitch genes (such as the slow MyHC isoform smyhc1
and the transcription factor prox1a) (von Hofsten et al., 2008;
Wang et al., 2011; Jackson et al., 2015).
Here, we observed that Sox6, at variance with Nfix, is ex-
pressed at comparable levels in embryonic and fetal myoblasts,
despite its role of inhibitor of slow twitching program. Intrigu-
ingly, we demonstrated that Sox6 has opposite roles in regu-
latingMyHC-I expression between embryonic and fetal myogen-
esis in mouse. Specifically, during embryonic myogenesis, Sox6
indirectly promotes MyHC-I expression via transcriptional acti-
vation of Mef2C. As a consequence, Sox6 deficiency in embry-
onic muscle leads to a strong downregulation of MyHC-I. On
the contrary, during fetal myogenesis, Sox6 cooperates with
Nfix to repress MyHC-I in a complex in which Nfix is necessary
for the proper binding of Sox6 to the MyHC-I promoter in fetal
myotubes. Finally, we show that Nfixa and Sox6 together regu-
late sMyHC in zebrafish embryos, revealing an evolutionarily
conserved mechanism that is required for the acquisition of
normal muscle phenotype.
RESULTS
Sox6 Transcriptionally Promotes MyHC-I Expression
during Embryonic Myogenesis
Sox6 has been intensively studied as an inhibitor of slow muscle
phenotype during the fetal period. However, we observed that
Sox6 is also expressed during embryonic myogenesis, which
is mainly characterized by the expression of typical slow genes
such as the slow MyHC isoform MyHC-I. Myf5GFP-P/+ embryos
and fetuses were collected at E12.5 or E16.5, and GFP-positive
myoblasts were isolated via fluorescence-activated cell sorting
(FACS) as previously described (Messina et al., 2010). Using
quantitative real-time PCR and western blot, we found that
Sox6 levels do not significantly change, whereas Nfix, as known,
is drastically upregulated in fetal progenitors (Figures 1A–1C).
Importantly, these data show that Sox6 and Nfix proteins are
co-expressed only during fetal myogenesis. We also performed
extensive immunofluorescence analysis on frozen mouse em-
bryo sections from E10.5 to E18.5 in order to follow Sox6 protein
expression throughout development. Notably, Sox6 is first ex-
pressed between E11.5 and E12.5 in primary fibers that express
high levels of MyHC-I (Figures S1A–S1H), whereas at E17.5, the
localization of Sox6 is almost completely associated with sec-
ondary fibers that are negative for MyHC-I (Figures S1I–S1L),
as previously described (An et al., 2011; Richard et al., 2011).
We therefore decided to investigate the possible function of
Sox6 during embryonic myogenesis, a function not apparently
linked to repression of MyHC-I. To this aim, we performed immu-
nofluorescence analysis on E12.5 muscle sections from homo-zygous mice carrying the Sox6lacZ allele (hence referred to as
Sox6-null mice) (Smits et al., 2001). Surprisingly, the staining
for MyHC-I is strongly decreased in Sox6 null in comparison to
wild-type (WT) muscle (Figures 1D and 1E). Importantly, no dif-
ferences in total MyHC content were assessed in embryonic
muscle groups of Sox6-null embryos (Figures 1G and 1H),
implying that the decrease in MyHC-I expression is not due to
delayed or aberrant muscle differentiation. We also performed
western blot and quantitative real-time PCR on embryonic
muscle lysates to confirm the immunofluorescence data, and
our results showed a decrease of MyHC-I protein in Sox6-null
samples, without major changes in total MyHC content (Figures
1J and 1K). Interestingly, the phenotype of Sox6-null embryonic
muscle is reminiscent of the Tg:Mlc1f-Nfix2 gain-of-function em-
bryo (Figures 1F and 1I), in which the Nfix2 splice variant is
ectopically expressed in muscle cells from E11.5, leading to a
fetal-like muscle phenotype (Kelly et al., 1997; Messina et al.,
2010). Importantly, Nfix expression in embryonic skeletal muscle
is not altered in the absence of Sox6 at both the protein and
mRNA levels (Figures S2A–S2D). Taken together, these results
show that Sox6 is expressed at equal levels in skeletal muscle
during embryonic and fetal myogenesis and that deletion of
Sox6 during the embryonic period unexpectedly leads to down-
regulation of MyHC-I.
Sox6Positively Regulates theSlow-Twitch Phenotype of
Embryonic Myoblasts by Binding to Mef2C Promoter
In order to define a possiblemechanism bywhich Sox6 regulates
the transcription of MyHC-I during embryonic myogenesis, we
performed chromatin immunoprecipitation (ChIP) for Sox6 in
differentiated embryonic myoblasts. We found that Sox6 does
not significantly bind either to the proximal or to the distal regu-
lative regions upstream of MyHC-I (Figure 2A), thus suggesting
that Sox6 is not able to directly regulate MyHC-I transcription
in embryonic muscle. To confirm this hypothesis, we performed
luciferase assays on WT and Sox6-null embryonic differentiated
myoblasts with vectors containing the 3,500-bp MyHC-I full
50-upstream region (MyHC-I 3500), the 408-bpMyHC-I proximal
promoter sequence (MyHC-I 408), or the mutated forms of
the distal and proximal canonical Sox6 binding sites, MyHC-I
3500 m and MyHC-I 408 m (Figure S3A) (Hagiwara et al., 2007;
An et al., 2011). As expected, in the absence of Sox6, we found
a significant reduction of firefly luciferase activity in all the
conditions with the only notable exception of the 408 WT
construct (Figure 2B), suggesting that Sox6 is promoting
MyHC-I expression in embryonic myocytes without direct bind-
ing to its canonical binding sites. In order to identify a possible
indirect mechanism by which Sox6 enhances MyHC-I expres-
sion in embryonic muscle, we focused on the transcription factor
Mef2C, a known positive regulator of the slow phenotype (Wu
et al., 2000; Potthoff et al., 2007; Anderson et al., 2015). To verify
the interaction between Mef2C and theMyHC-I promoter in em-
bryonic myoblasts, we performed a ChIP assay, which showed
direct binding of Mef2C on the proximal MyHC-I promoter (Fig-
ure S3B). Interestingly, Mef2C mRNA is downregulated in
E12.5 Sox6-null muscle, at variance with the closely related
Mef2A (Figure 2C). By ChIP on embryonic differentiated myo-
blasts, we found that Sox6 directly binds to a region located inCell Reports 17, 2354–2366, November 22, 2016 2355
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Figure 1. Sox6 Acts a Positive Regulator of the Slow-Twitch Phenotype during Embryonic Myogenesis
(A) Quantitative real-time PCR analysis on freshly isolatedMyf5GFP-P/+ embryonic (E12.5) and fetal (E16.5) myoblasts showing relative expression ofSox6 andNfix
transcripts in the two populations.
(B) Western blot on lysates from freshly isolated Myf5GFP-P/+ embryonic and fetal myoblasts. b-Tubulin was used to normalize the amount of protein loaded.
(C) Quantitative densitometry of the protein expression levels of Sox6 and Nfix at E12.5 and E16.5.
(D–I) Immunofluorescence on E12.5 muscle sections fromWT (D and G), Sox6 null (E and H), and Tg:Mlc1f-Nfix2 (F and I) mice stained with anti-MyHC-I (D–F) or
anti-MyHCs (MF20) antibodies (G-I). Dashed lines highlight the forelimb anlagen contour. Scale bars, 100 mm.
(J) Western blot on E12.5 muscle samples from WT, Sox6 null, and Tg:Mlc1f-Nfix2 mice. Vinculin was used to normalize the amount of loaded proteins.
(K) Quantitative real-time PCR on E12.5 muscle tissue from WT and Sox6-null mice (*p < 0.05; **p < 0.01; n = 3).
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B Figure 2. Sox6 Indirectly Activates MyHC-I
Expression in Embryonic Myoblasts via a
Mef2C-Dependent Mechanism
(A) ChIP assay with anti-Sox6 antibody on E12.5 differ-
entiated myoblasts. Three different chromatin regions
were tested: a negative control region (intergenic)
located 15 kb upstream of MyHC-I TSS, the MyHC-I
proximalpromoter (375bp;MyHC-Ipromoter),andthe
MyHC-I distal enhancer (2,900 bp;MyHC-I enhancer).
(B) Luciferase report assay on WT and Sox6-null
E12.5 differentiated myoblasts transfected with
control pGL3-basic, MyHC-I 408, MyHC-I 408 m,
MyHC-I 3,500, and MyHC-I 3,500 m constructs (*p <
0.05; **p < 0.01; n = 2).
(C) Quantitative real-time PCR for Mef2C and Mef2A
on E12.5 muscle tissue from WT and Sox6-null mice
(**p < 0.01; n = 2).
(D) ChIP assay with anti-Sox6 antibody on E12.5
differentiated primary myoblasts showing binding of
Sox6 to a region located 1.1 kb upstream ofMef2C
TSS (***p < 0.001; n = 3). As negative control, we used
the MyHC-I 15 kb intergenic region.
(E) Quantitative real-time PCR forMyHC-I andMyHC-
emb (MyHC-I/MyHC-emb ratio) on WT and Sox6-null
differentiated embryonic myoblasts transfected with
a Mef2C-overexpressing vector (*p < 0.05; **p < 0.01;
n = 2).
(F) Quantitative real-time PCR for MyHC-I on embry-
onic myoblasts purified from Myf5GFP-P/+ mice, in-
fected with scramble or shSox6 virus. Myf5GFP-P/+
purified embryonic myoblasts infected by lentiviruses
expressing the shRNA for Sox6 were transfected with
Mef2C-overespressing vector (***p < 0.001; n = 2).the Mef2C promoter (Figure 2D), indicating that Sox6 is a direct
activator of Mef2C during embryonic myogenesis. In order to
validate a possible Mef2C-mediated mechanism of MyHC-I
regulation, we transfected WT and Sox6-null unpurified embry-
onic myoblasts with a vector overexpressing Mef2C. Mef2C
overexpression in Sox6-deficient cells (Figure S3C) leads to an
increase of MyHC-I expression when normalized on the levels
ofMyHC-emb to account for the total number of myogenic cells
(Figure 2E). To validate these data, we also transduced purified
embryonic myoblasts with a lentiviral vector expressing small
hairpin RNA (shRNA) against Sox6 to achieve in vitro Sox6
knockdown (Figure S3D). We then transfected cells with
Mef2C-overexpression vector (Figure S3D) and assessed the
levels ofMyHC-ImRNAbyquantitative real-timePCR (Figure 2F).
Strikingly, overexpression of Mef2C was able to partially rescue
MyHC-I expression in shSox6 cells (up to 30% of the levels of
scramble-transduced cells). These results show that during the
embryonic period, Sox6 acts indirectly as a positive regulator
ofMyHC-I via aMef2C-dependentmechanism, in sharp contrast
with its well-known and characterized function during fetal myo-
genesis (An et al., 2011; Quiat et al., 2011; see below).Cell RepoSox6 Is Necessary for Nfix Binding to
theMyHC-I Promoter during the Fetal
Period
Since Sox6 has opposite roles in MyHC-I
regulation in embryonic and fetal muscle,and since Nfix is only expressed during fetal myogenesis (Mes-
sina et al., 2010), we decided to investigate the possible cooper-
ation between Nfix and Sox6 during fetal myogenesis. We first
investigated Nfix expression and function in Sox6-null fetuses
(E16.5). As previously described in other Sox6-null mouse
models (Hagiwara et al., 2007; An et al., 2011; Quiat et al.,
2011), fetal fiber specification is completely disrupted in the
absence of Sox6. Indeed, in contrast to WT, Sox6-null fetal mus-
cle displays very high levels of MyHC-I by immunofluorescence,
quantitative real-time PCR, and western blot (Figures S4A–S4D).
We also looked at Nfix on sections from the Sox6-null mice and
found that despite the dramatic increase in MyHC-I expression,
Nfix is correctly expressed in the nuclei of muscle fibers in the
absence of Sox6 (Figures 3A–3D), and western blot analysis
did not reveal differences in Nfix protein content (Figure S4C).
These data suggest that Nfix is normally expressed in fetal mus-
cles lacking Sox6 but unable to properly repress MyHC-I. To
verify whether Sox6 is required for Nfix function, we performed
ChIP for Nfix in WT fetal myotubes, which revealed binding of
Nfix to MyHC-I promoter in the same region of the proximal
Sox6 binding site (200 bp) (Figure 3E). Interestingly, werts 17, 2354–2366, November 22, 2016 2357
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Figure 3. Sox6 Is Required for Normal Nfix
Function in Fetal Muscle
(A–D) Immunofluorescence with anti-Nfix (green)
and anti-MyHC-I (red) antibodies on E16.5 muscle
sections from WT (A and B) or Sox6-null (C and D)
mice. Arrows indicate Nfix-positive nuclei in
secondary (MyHC-I negative) fibers. Arrowheads
indicate Nfix-positive nuclei in MyHC-I-positive
fibers. Nuclei are counterstained with Hoechst.
Scale bars, 25 mm. Higher magnifications of Nfix-
positive fibers are shown in the insets.
(E) ChIP assay with anti-Nfix antibody on WT and
Sox6-null E16.5 myotubes on negative control
region (intergenic) located 15 kb upstream of
MyHC-I TSS, the MyHC-I proximal promoter
(375 bp; MyHC-I promoter), and the Nfatc4
promoter region (1.2 kb upstream of the Nfatc4
TSS) (*p < 0.05; **p < 0.01; n = 2).
(F) Luciferase report assay on WT and Nfix-null
differentiated fetal myoblasts (E16.5) transfected
with control pGL3-basic, MyHC-I 408, andMyHC-I
408 m vectors (**p < 0.01; n = 2).observed that in Sox6-null fetal myotubes, the binding of Nfix to
the MyHC-I promoter is significantly reduced. Importantly, Nfix
binding to Nfatc4 promoter is not impaired in the absence of
Sox6 (Figure 3E), suggesting that Nfix is still able to bind to other
transcriptional targets in the absence of Sox6. We further vali-
dated the repressive role of Nfix on the MyHC-I proximal pro-
moter by performing a luciferase assay with MyHC-I 408 and2358 Cell Reports 17, 2354–2366, November 22, 2016MyHC-I 408 m vectors in WT and Nfix-
null fetal myotubes (Figure 3F). Our results
showed increased luciferase expression
in the absence of Nfix with the vector car-
rying the WT sequence, suggesting that
indeed Nfix represses MyHC-I by acting
on the proximal promoter regulative re-
gion, in spite of the absence of any Nfix
consensus sequences (data not shown).
Importantly, Nfix-dependent negative
regulation of MyHC-I is lost when the
proximal Sox6 binding sequence is
mutated, demonstrating that Sox6 is
required for Nfix binding to the proximal
MyHC-I promoter (Figure 3F). Overall,
these results suggest a possible crosstalk
between Nfix and Sox6 in regulating
MyHC-I expression at the proximal pro-
moter region.
Nfix Is Necessary and Sufficient for
Sox6 Regulation of MyHC-I
Expression
To better investigate a possible recip-
rocal interplay between Nfix and Sox6,
we performed immunofluorescence for
Sox6 and total MyHC on frozen muscle
sections from E16.5 WT and Nfix-null
mice (Campbell et al., 2008). We foundthat Sox6 is expressed in both WT and Nfix-null muscles (Fig-
ures S4E and S4F), implying that Nfix is dispensable for normal
Sox6 expression in fetal muscle. Interestingly, immunofluores-
cence for Sox6 and MyHC-I on sections from the same mice
revealed that in the absence of Nfix, there is a marked increase
in the number of Sox6-positive fibers that co-express MyHC-I,
in contrast to WT muscles (Figures 4A–4D). We further
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Figure 4. Nfix Is Necessary for the Correct Func-
tion of Sox6 in Fetal Muscle
(A–D) Immunofluorescence with anti-Sox6 (green) and
anti-MyHC-I (red) antibodies on fetal (E16.5) muscle
sections from WT (A and B) and Nfix-null (C and D) mice.
Arrows indicate secondary fibers, which present nuclear
Sox6 expression and low or absent staining for MyHC-I.
Arrowheads indicate fibers co-expressing nuclear Sox6
and MyHC-I. Nuclei are counterstained with Hoechst.
Scale bars, 25 mm. Higher magnifications are shown in
the insets.
(E) Western blot on lysates from WT and Nfix-null E16.5
myotubes. b-Tubulin was used to normalize the amount
of proteins loaded.
(F) Quantitative real-time PCR on WT and Nfix-null E16.5
myotubes (**p < 0.01; n = 3).validated these data by western blot and quantitative real-time
PCR on differentiated fetal myotubes and observed that Nfix-
null myotubes express higher levels of MyHC-I than WT cells
(Figures 4E and 4F). These data show that in the absence of
Nfix, the repressive activity of Sox6 on MyHC-I is partially
impaired, even if the normal expression pattern of Sox6 is
maintained. The results obtained in both Sox6 and Nfix-null fe-
tuses led us to hypothesize a functional cooperation between
Nfix and Sox6 in MyHC-I regulation. Therefore, we tested the
ability of Nfix and Sox6 to bind to each other in a multi-protein
complex. To this aim, we used fetal myotubes transiently trans-
fected with an Nfix2 hemagglutinin (HA) vector (see Experi-
mental Procedures) and performed a co-immunoprecipitation
(coIP) assay from nuclear extracts for HA and Sox6. CoIP re-
vealed the presence of a complex containing both Sox6 and
Nfix2-HA, as shown in Figure 5A. Therefore, we wondered
whether, as observed for Nfix fetuses in absence of Sox6,
Nfix might be required for the binding of Sox6 to the MyHC-I
promoter as well. Hence, we performed ChIP for Sox6 in WT
and Nfix-null fetal myotubes. Our results showed a decrease
in Sox6 binding to the two different sites in the MyHC-ICell R50-upstream region (Figure 5B). Notably, the
binding with the proximal promoter was
completely lost in the absence of Nfix,
whereas the binding with the distal enhancer
was reduced by 50%. Interestingly, ChIP for
Sox6 on the Mef2C promoter reveals that in
WT fetal myotubes, Sox6 is not able to bind
to the Mef2C promoter, at variance with
what happens during the embryonic stage.
On the contrary, Sox6 binding on the Mef2C
promoter still occurs in Nfix-null fetal myo-
tubes. These data indicate that Nfix is
required for the proper binding of Sox6 to
the MyHC-I promoter during fetal myogene-
sis. Finally, we performed ChIP for Sox6 on
WT and Tg:Mlc1f-Nfix2 embryonic myoblasts
(Figure 5C). Strikingly, Nfix overexpression
leads to a switch in the binding properties of
Sox6; indeed, we found that Sox6 is bound
to the MyHC-I promoter, but not to theMef2C promoter, in Tg:Mlc1f-Nfix2 embryonic myoblasts.
These data demonstrate that Nfix is necessary and sufficient
for the binding of Sox6 to the MyHC-I proximal promoter and
therefore for Sox6 repressive activity on MyHC-I.
Functional Cooperation of Sox6 and Nfixa Is
Evolutionarily Conserved in Zebrafish
It was previously demonstrated that both Sox6 and Nfixa have
an evolutionarily conserved role in the repression of slow-twitch
genes in zebrafish (von Hofsten et al., 2008; Pistocchi et al.,
2013; Jackson et al., 2015). We thus wondered whether a func-
tional interplay between Nfixa and Sox6 is conserved in zebra-
fish myogenesis. As a preliminary analysis, we performed quan-
titative real-time PCR on trunk and tail regions isolated from
zebrafish embryos at 1, 2, and 3 days post-fertilization (dpf)
and found that the sox6 transcript is expressed at high levels
at 1 dpf and is steadily downregulated up to 3 dpf (Figure S5A),
whereas the nfixa transcript peaks at 2 dpf (Figure S5B),
as shown previously (Pistocchi et al., 2013). Additionally, we
performed immunofluorescence for Sox6 and total MyHC
(MF20 antibody) or the slow MyHC isoform sMyHC (F59eports 17, 2354–2366, November 22, 2016 2359
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Figure 5. Nfix Is Required for Fetal-Spe-
cific Binding of Sox6 to MyHC-I Regulative
Regions
(A) Immunoprecipitation assay, from nuclear ex-
tracts, on fetal myoblasts transfected with Nfix2-
HA vector, showing the immunoprecipitation of
Sox6 (IP Sox6) and HA (IP HA). T, total lysate; IgG,
negative control; IP, immunoprecipitated. The
coIPs for Sox6 on Sox6-null myotubes and for HA
on fetal myoblasts transfected with the HA-only
expressing vector (pCH-HA) were used as nega-
tive controls.
(B) ChIP assay with anti-Sox6 antibody onWT and
Nfix-null E16.5 myotubes on the same chromatin
regions described in Figures 2A and 2D (*p < 0.05;
**p < 0.01; ***p < 0.001; n = 2). As a negative
control, we used only the MyHC-I 15 kb region.
(C) ChIP assay on unpurified embryonic myo-
blasts from WT or Tg:Mlc1f-Nfix2 to test Sox6
binding on MyHC-I and the Mef2C promoter. The
intergenic region was used as a negative control
and IgG as an unrelated antibody (**p < 0.01;
***p < 0.001; n = 2).antibody) on 2 dpf embryos and found that Sox6 protein is spe-
cifically expressed in the nuclei of fast muscle fibers that are
negative for sMyHC (Figures 6A and 6B), whereas the outer su-
perficial fibers positive for sMyHC are mostly negative for Sox6
(data not shown). Interestingly, we observed that a minority of
slow superficial fibers show cytoplasmic staining for Sox6 (Fig-
ures 6C–6J), suggesting that Sox6 subcellular localization might
be spatially regulated in the different muscle domains. In order
to elucidate the role of Sox6 in slow-twitch genes regulation, we
performed morpholino (MO)-mediated knockdown of sox6 (von
Hofsten et al., 2008). By quantitative real-time PCR analysis
(Figures S5C and S5D), we found that the expression of smyhc1
is markedly increased in sox6 morphants at 2 dpf, whereas the
fast-twitch gene mylpfa (fast myosin light chain isoform) is ex-
pressed at equal levels. Moreover, the nfixa transcript is drasti-2360 Cell Reports 17, 2354–2366, November 22, 2016cally upregulated in sox6 morphants,
suggesting that Sox6 might negatively
regulate nfixa (Figure S5E). We conclude
that Sox6 is a critical repressor of the
slow-twitch phenotype in zebrafish and
that Nfixa is not able to compensate for
sox6 knockdown. To verify a possible
cooperation between Nfixa and Sox6,
we performed co-injections of morpholi-
nos against sox6 and nfixa at lower
doses with respect to those previously
described (von Hofsten et al., 2008; Pis-
tocchi et al., 2013) in order to minimize
their effect when injected separately
(see Experimental Procedures). Co-injec-
tion of these doses of MOs resulted in
synergistic defects in motility in touch-
response assays (Figure S6). Control em-
bryos and the vast majority of sox6 or
nfixa morphants readily swam awaywhen touch-stimulated. On the contrary, 66% of double partial
morphants were either shivering or bending their tails before
eventually moving away but within a shorter distance (Figures
S6A and S6C; Movie S1). The synergistic effect is more evident
when lowering the doses (see Figures S6B and S6D). Strikingly,
quantitative real-time PCR results show that smyhc1 is signifi-
cantly upregulated only in the double morphants at 48 hpf,
whereas the level of myl1, an early marker for differentiating
fast muscle cells (Burguie`re et al., 2011), does not change (Fig-
ure 6K). Moreover, we validated the increased expression of
sMyHC (F59 antibody) in sox6/nfixa double morphants by
western blot (Figure 6L). We thus conclude that functional
cooperation of Sox6 and Nfix is required for proper skeletal
muscle development and that this cooperation is evolutionarily
conserved in mouse and zebrafish.
A B
C D
E F
K L
Figure 6. Functional Cooperation of Sox6 and Nfixa Is Conserved in Zebrafish
(A–J) Immunofluorescence with anti-Sox6 antibody (green) and anti-MyHC antibody (red) (A, B, and G–J) or with anti-Sox6 (green) and anti-sMyHC (F59, red)
(C–F) on 2 dpf zebrafish muscle longitudinal sections. Arrowheads indicate Sox-positive nuclei in fast-twitch muscle fibers. Arrows indicate Sox6 staining in the
cytoplasm of superficial slow fibers. Approximately one-fifth of the sMyHC-positive superficial cells displayed cytoplasmic Sox6 staining, whereas fast fibers
negative for sMyHC only displayed nuclear Sox6 staining. Nuclei are counterstained with Hoechst. Scale bars, 25 mm.
(legend continued on next page)
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DISCUSSION
Adult skeletal muscle is composed of two major fiber types pre-
senting a wide range of physiological and biochemical differ-
ences. Slow-twitch type I fibers use oxidative metabolism and
express the slow MyHC isoform MyHC-I; in contrast, fast-twitch
type II fibers present glycolytic or mixed metabolism and ex-
press three fast MyHC isoforms (MyHC-IIa, IIx/d, and IIb) (Peter
et al., 1972; Schiaffino et al., 1988; Chakkalakal et al., 2012). The
phenotype of post-natal muscle fibers is strictly regulated by
extrinsic signals such as muscle activity and hormones (But-
ler-Browne et al., 1982; Gambke et al., 1983; Russell et al.,
1988). Additionally, different factors controlling adult muscle
plasticity have been identified, including the Nfatc (Calabria
et al., 2009) and Mef2 (Wu et al., 2000; Potthoff et al., 2007; An-
derson et al., 2015) transcription factor families and PGC-1a (Li
et al., 2002). On the contrary, the molecular mechanisms by
which muscle fiber diversity is achieved during pre-natal devel-
opment are still poorly understood. It was shown that the
intrinsic transcriptional properties of embryonic and fetal
myogenic progenitors are important to set the fiber type in the
absence of nerve activity (Cho et al., 1993; Cusella-De Angelis
et al., 1994). Moreover, in recent years, several transcription
factors contributing to developmental muscle fiber specification
have been identified, including Sox6 (Hagiwara et al., 2007; An
et al., 2011), Nfix (Messina et al., 2010), Six1/Six4 (Richard et al.,
2011), and Nfatc2 (Daou et al., 2013). However, the network
of transcription factors controlling fiber specification during
embryogenesis is still far from being fully characterized, and
until now, functional interactions among the different regulators
were completely unknown.
In this work, we provided evidence for functional interplay be-
tween Nfix and Sox6 in controlling expression of the slow MyHC
isoform during mouse pre-natal muscle development.
In contrast to Nfix, which is a specific marker of fetal myogen-
esis (Messina et al., 2010; Mourikis et al., 2012), Sox6 is ex-
pressed in both embryonic and fetal purified myoblasts at the
mRNA and protein levels. Consistently, we found that Sox6 pro-
tein is expressed in skeletal muscle in vivo starting between
E11.5 and E12.5. This was unexpected, since Sox6 is known
to be a repressor of MyHC-I, which along with MyHC-emb is ex-
pressed in all embryonic fibers (Hagiwara et al., 2007; Hutche-
son et al., 2009). It is known that Sox6 transcript is absent in
mouse primary myotome between E9.5 and E10.75 (Vincent
et al., 2012), suggesting that Sox6 is quickly activated in embry-
onic myoblasts at the beginning of primary myogenesis. Unex-
pectedly, Sox6 deficiency during primary myogenesis leads to a
transient faster muscle phenotype with low levels of MyHC-I.
This is followed in Sox6-null fetuses by dramatic upregulation
of MyHC-I at the transcription level, consistently with previous
characterizations of the Sox6-null phenotype (Hagiwara et al.,
2007; An et al., 2011; Quiat et al., 2011). Our results demon-(K) Quantitative real-time PCR analysis on trunk and tail regions at 48 hpf from
sox6-MO (0.1 pmol), or nfixa-MO + sox6-MO (**p < 0.01; N = 2).
(L) Western blot for sMyHC at 52 hpf on trunk and tail regions of embryos injected
MO. Vinculin was used to normalize the amount of loaded proteins.
2362 Cell Reports 17, 2354–2366, November 22, 2016strate that Sox6 plays opposite roles in MyHC-I expression dur-
ing development. Importantly, in embryonic myogenic cells,
Sox6 does not bind to the two canonical MyHC-I binding sites,
which are both dispensable for Sox6-dependent embryonic
regulation of MyHC-I, at least in our culturing conditions. These
data strongly suggest an indirect mechanism of regulation. We
found that Sox6 directly binds to the promoter ofMef2C and ac-
tivates its expression in primary myofibers. Mef2C is part of a
transcription factor family that is constitutively expressed in
muscle cells since early embryogenesis (Edmondson et al.,
1994) and plays an important role in the specification and main-
tenance of type I fibers (Chin et al., 1998; Wu et al., 2000; Ander-
son et al., 2015). Importantly, conditional deletion of Mef2C in
skeletal muscle leads to a drastic reduction in slow-twitch fibers
(Potthoff et al., 2007). Our rescue experiment, although partial,
clearly shows that one of the Sox6-dependent effects on
MyHC-I transcription in embryonic myofibers is mediated by
Mef2C, which is directly targeted by Sox6 in embryonic, but
not fetal, muscle. This function led us to hypothesize that the
binding ability of Sox6 is differentially regulated in discrete
myogenic progenitor populations or at different times during
development according to different co-factors, which contribute
to the high versatility of Sox6 functions. It is known that SoxD
factors, lacking trans-acting functional domains, have a critical
requirement for co-factors in order to regulate transcription of
target genes (reviewed in Hagiwara, 2011). Therefore, it is likely
that the reversal in Sox6 function is due to different factors that
are progressively recruited and activated during muscle devel-
opment. Indeed, we found that during fetal myogenesis, Nfix
acts as a fundamental co-factor of Sox6 and is able to form a
complex with Sox6, which is no longer able to bind to the
Mef2C promoter but can bind to MyHC-I regulative regions, in
particular the proximal promoter that was shown to be critical
for Sox6-dependent fetal repression of MyHC-I (Hagiwara
et al., 2007). In our previous study, we showed that Nfix nega-
tively regulates MyHC-I by repressing Nfatc4, a positive regu-
lator of MyHC-I (Messina et al., 2010). Interestingly, we have
now found that during fetal myogenesis, Nfix is also present
at the MyHC-I proximal promoter along with Sox6, suggesting
that a physical association between these two proteins may
be required for proper MyHC-I downregulation. Since Nfix pre-
sents both a trans-repression domain and a trans-activation
domain, we hypothesized that formation of a complex with
Sox6 might provide the basis for the transcriptional repression
at the MyHC-I locus (Figure 7). Indeed, Nfix and Sox6 were
found to be part of the same complex in fetal myotubes and
are both present at the MyHC-I proximal promoter. Moreover,
our study on Nfix-null and Sox6-null fetuses clearly shows that
Sox6 and Nfix are independently expressed during secondary
myogenesis and that neither Sox6 nor Nfix is able to correctly
downregulate MyHC-I expression when the other one is not pre-
sent. A scheme of the scenario in which Sox6 and Nfix behaveembryos injected with std-MO or suboptimal doses of nfixa-MO (0.25 pmol),
with std-MO or suboptimal doses of nfixa-MO, sox6-MO, or nfixa-MO + sox6-
Figure 7. Model of Sox6 and Nfix Interplay
during Pre-natal Myogenesis
Scheme illustrating the functions of Sox6 and Nfix
during embryonic (E12.5) and fetal (E16.5) myo-
genesis. Transcription factors are represented by
circles, whereas the regulative region of MyHC-I is
indicated by rectangles that are green when tran-
scription is activated and red when transcription is
repressed.and cooperate during pre-natal muscle development is shown
in Figure 7.
In this work, we have also provided evidence for a conserved
transcriptional cooperation of Sox6 and Nfixa in zebrafish. We
have shown that Sox6 is crucial for the regulation of smyhc1, in
line with the findings of Jackson et al. (2015). It was shown that
Sox6 expression is silenced in zebrafish slow fibers by the com-
bined effects of Prdm1a and miR-499 (von Hofsten et al., 2008;
Wang et al., 2011). We found that a minority of sMyHC-positive
cells display cytoplasmic staining for Sox6, suggesting that
Sox6 might also be regulated through subcellular localization
in different fiber types. Notably, our double partial knockdown
performed with suboptimal doses of sox6-MO (von Hofsten
et al., 2008) and nfixa-MO (Pistocchi et al., 2013) caused a severe
impairment in the touch-evoked escape response, suggesting
that Sox6 and Nfixa cooperate in proper muscle function. Molec-
ularly, our data suggest that the two transcription factors can act
together to repress smyhc1 expression in zebrafish embryos,
whereas the expression of a typical fast-twitch gene, such as
myl1 (Burguie`re et al., 2011), was unaffected in double partial
morphants.
In conclusion, we have presented a complex model of regula-
tion of embryonic to fetal MyHC-I regulation that involves a
functional interplay between Nfix and Sox6 that is conserved in
mammals and teleosts.
EXPERIMENTAL PROCEDURES
Mouse Strains and Fish Lines
The following murine lines were used: Myf5GFP-P/+ (Kassar-Duchossoy et al.,
2004), Nfix null (Campbell et al., 2008), Sox6lacZ/+ (Smits et al., 2001), and
Tg:Mlc1f-Nfix2 (Messina et al., 2010). For each of these lines, the genotyping
strategy has been described in the references. CD1 WT mice (Jackson Lab-
oratory) were used as well. Mice were kept in pathogen-free and controlled
conditions, and all procedures conformed to Italian law (D. Lgs n 2014/26,
implementation of the 2010/63/UE) and were approved by the Animal Welfare
Body of the University of Milan and the Italian Minister of Health (1212/
2015PR). Zebrafish were raised and maintained according to established
techniques. The following line was used: AB (from Carole Wilson, UCL,
London, UK).Cell ReportImmunofluorescence on Sections
Mouse or zebrafish embryos were fixed in 4%
paraformaldehyde, extensively washed in PBS,
and incubated overnight in PBS containing 15%
sucrose. Samples were then frozen in nitrogen-
chilled isopentane and kept at 80C until use.
Cryostat sections (8 mm thick) were permeabilized
in 1% BSA, 0.2% Triton X-100 in PBS for 30 min
at room temperature and then incubated for 1 hr
in blocking solution (10% goat serum in PBS) andovernight with the primary antibody or with mock PBS. After incubation for
45 min with the fluorescent-conjugated secondary antibody (Jackson Immu-
noResearch Laboratories), sections were washed in PBS 0.2% Triton X-100
and mounted, and fluorescent immunolabeling was recorded with a DM6000
Leica microscope. The following primary antibodies were used: rabbit anti-
Sox6 (Abcam, 1:300), rabbit anti-Nfix (Novus Biological, 1:200), mouse anti-
MyHC-I (Sigma, 1:200), BAD5 (monoclonal, 1:2), MF20 (monoclonal, 1:2),
and F59 (monoclonal, 1:10). Nuclei were stained with Hoechst (1:1,000).
Cell Sorting and Culturing
Dissected Myf5GFP-P/+ embryonic or fetal muscles were digested by 0.15 mg/
mL Collagenase (Sigma), 1.5 mg/mL Dispase (GIBCO), and 0.1 mg/ml Dnase I
(Sigma) for 30min at 37C in agitation as described in Biressi et al. (2007). After
centrifugation and filtration, cells were collected in DMEM, 20% fetal bovine
serum (FBS), 2 mM EDTA, and 20 mM HEPES. For cell sorting, we used the
Sorter BD FACSAria. GFP-positive cells were collected for mRNA and protein
extraction. For the preparation of unpurified fetal myoblasts after digestion of
tissue, cells were pre-plated for 30 min on a plastic dish to lose fibroblasts,
which normally adhere to plastic. Unpurified cells were kept in incubation
at 37C in 20% HS (20% horse serum in DMEM) and 24 hr later allowed to
differentiate in DM (2% horse serum in DMEM) for 48 hr.
Lentivirus Production, Transduction, and Transfection
Preparation of viral particles were performed by co-transfecting pLKO.1-
shSox6 vectors (Thermo Fisher Scientific) or non-targeting shRNA vectors
(30 mg), together with the packaging plasmids pMDLg/p (16.25 mg),
pCMV-VSVG (9 mg), and pRSV-REV (6.25 mg), in HEK293T cells. Transfec-
tion was performed using the calcium phosphate transfection method.
Viral particles were collected 40 hr after transfection and subjected to
ultracentrifugation at 20,000 rpm for 2 hr at 20C (Beckman Coulter, Optima
L-100 XP). The concentrated viral particles were re-suspended in PBS and
stored in aliquots at 80C until further use. Embryonic myoblasts were
transduced by overnight incubation with viral preparation. These prepara-
tions were used to transduce embryonic myoblasts at an MOI of 10. The
day after transduction, embryonic myoblasts were transfected with Mef2C
(pCDNAI/A-Mef2C) or the empty vector as a negative control using Lipofect-
amine LTX (Invitrogen).
Protein Extraction and Western Blot
Cultured cells were washed twice in ice-cold PBS and then lysed (30min in ice)
with RIPA buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1% Triton-X, 0.1%
sodium deoxycholate, 0.1% SDS, and 150 mM NaCl in deionized water)
plus protease inhibitors (1 mMPMSF). For zebrafish, only trunk and tail regions
were used, cutting out the head, and protein was extracted in Laemmli buffers 17, 2354–2366, November 22, 2016 2363
(3 mL per embryo). Protein was harvested after centrifugation, quantified
by absorbance reading at 750 nm, and stored at 80C. 30 mg protein was
resolved on 8%–12% polyacrylamide gels or on MiniProtean TDX Gels (Bio-
Rad) after denaturation at 95C for 5 min with SDS-PAGE Loading sample
buffer 2X (100 mM Tris [pH 6.8], 4% SDS, 0.2% Bromophenol blue, 20% glyc-
erol, and 10 mM dithiothreitol). For western blot analysis, proteins were trans-
ferred onto nitrocellulose with the iBlot Dry Blotting System (Invitrogen).
Following transfer, membranes were blocked in 5%milk in Tris-buffered saline
(TBS)-T (TBS plus 0.02% Tween20) for 1 hr at room temperature. The primary
antibodies used were rabbit anti-Sox6 (Abcam; 1:1,000), mouse anti-MyHC-I
(Sigma; 1:5,000), mouse anti-b-tubulin (Santa Cruz Biotechnology; 1:5,000),
rabbit anti-Nfix (Novus Biologicals; 1:500), mouse anti-HA (Covance; 1:500),
mouse anti-vinculin (Sigma; 1:1,000), and mouse anti-sMyHC (F59,
Hybridoma Bank) anti-mouse sarcomeric MyHC (MF20, Hybridoma Bank).
Horseradish peroxidase (HRP)-conjugated antibodies (Bio-Rad) were used
as secondary antibodies, and the signal was revealed with the ChemiDoc
MP System (Bio-Rad).
Transfection and Co-immunoprecipitation Assays
For transfection of fetal myoblasts, WT or Sox6-null cells were plated on
90-mm dishes and allowed to reach 80% confluence in proliferating condi-
tions. Cells were transfected with pCH-Nfix2-HA or pCH-HA plasmids with
Lipofectamine LTX (Invitrogen) overnight at 37C. Cells were kept in DM for
36 hr after transfection, and then nuclear extracts were prepared by collecting
5 3 106 cells in 400 mL ice-cold hypotonic buffer A (10 mM HEPES [pH 7.9],
10 mM KCl, 0.1 mM EGTA, 1 mM DTT, protease inhibitors, 1 mM PMSF,
and phosphatase inhibitors) for 15 min in ice. Then, NP40 was added to a final
concentration of 0.625%, and cells were centrifuged at 5,000 rpm for 5 min at
4C. The supernatant was discarded as cytoplasmatic extract, while the
pelleted nuclei were resuspended in 100 mL immunoprecipitation lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 1% NP40, 1 mM EDTA, 100 mM NaCl,
and protease and phosphatase inhibitors. Immunoprecipitation was per-
formed using the immunoprecipitation kit Dynabeads Protein A (Life Technol-
ogies). Dynabeads Protein A (50 mL) was incubated for 2 hr with gentle rotation
at room temperature with 5 mg rabbit anti-Sox6 antibody (Abcam), rabbit anti-
HA antibody (Santa Cruz), or non-related rabbit immunoglobulin G (IgG) (Santa
Cruz). Then, the bead-antibody complex was incubated with gentle rotation for
2 hr at 4C with 1.5 mg total protein lysates per condition. The eluted proteins
were denatured with non-reducing SDS-PAGE loading sample buffer (100 mM
Tris [pH 6.8], 4%SDS, 0.2% bromophenol blue, and 20% glycerol) and loaded
onto a gel.
Chromatin Immunoprecipitation and Reporter Assay
ChIP for Sox6 and luciferase assays were performed as previously published
(An et al., 2011). For the detailed protocol, see Supplemental Experimental
Procedures.
RNA Extraction and Analysis
RNA from homogenized mouse or zebrafish embryos and isolated cells
was extracted with NucleoSpin RNA kits (Macherey-Nagel) following the man-
ufacturer’s instructions. Eluted RNA was checked on agarose gels, quantified
with a Nanodrop spectrophotomer, and stored at 80C. Approximately
0.5 mg RNA was used with the ImProm-II Reverse Transcriptase kit (Promega).
Real-time PCR was performed on cDNA using SYBR Green Supermix (Bio-
Rad) and the CFX Connect Real Time System (Bio-Rad). After amplification,
relative mRNA expression levels were calculated using standard curves from
cDNA dilutions and normalized on the Gapdh expression levels. For quantita-
tive real-time PCR in zebrafish, we used rpl8 to normalize themRNA levels. The
primers used are listed in Tables S1 and S2.
MO Microinjections
The antisense MOs (Gene Tools) used in this study, sox6-MO1 (von Hofsten
et al., 2008) and nfixa-MO (Pistocchi et al., 2013), were previously described.
MOs, diluted in Danieau buffer (Nasevicius and Ekker, 2000), were injected at
the one- to two-cell stage. Escalating doses of each MO were tested for
phenotypic effects; as control for unspecific effects, each experiment was
performed in parallel with an std-MO (standard control oligo) with no target2364 Cell Reports 17, 2354–2366, November 22, 2016in zebrafish embryos. We usually injected 0.25 pmol sox6-MO per embryo.
For combined knockdown experiments, we injected sox6-MO and nfixa-MO
at 0.1 and 0.25 or 0.08 and 0.125 pmol per embryo, respectively.
Statistical Analysis
Values were expressed as means ± SD. Statistical significance was assessed
by unpaired Student’s t test with Prism 5 software. Statistical significance with
a probability of less than 5%, 1%, or 0.1% is indicated in each graph with a
single, double, or triple asterisk, respectively, followed by the number of inde-
pendent experiments (n).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, two tables, and one movie and can be found with this article online
at http://dx.doi.org/10.1016/j.celrep.2016.10.082.
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